238 related articles for article (PubMed ID: 32711543)
1. Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway.
Hori Y; Hirose K; Aramaki-Hattori N; Suzuki S; Nakayama R; Inoue M; Matsui T; Kohara M; Toyosawa S; Morii E
Diagn Pathol; 2020 Jul; 15(1):98. PubMed ID: 32711543
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
[TBL] [Abstract][Full Text] [Related]
3. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. Case Report of Fibro-Adipose Vascular Anomaly (FAVA) with Activating Somatic
Driskill JH; Hwang H; Callan AK; Oliver D
Case Rep Genet; 2022; 2022():9016497. PubMed ID: 35967928
[TBL] [Abstract][Full Text] [Related]
6. Fibro-adipose vascular anomaly (FAVA) - diagnosis, staging and management.
Wang H; Xie C; Lin W; Wang P; Yang W; Guo Z
Orphanet J Rare Dis; 2023 Nov; 18(1):347. PubMed ID: 37936141
[TBL] [Abstract][Full Text] [Related]
7. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
8. Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity.
Alomari AI; Spencer SA; Arnold RW; Chaudry G; Kasser JR; Burrows PE; Govender P; Padua HM; Dillon B; Upton J; Taghinia AH; Fishman SJ; Mulliken JB; Fevurly RD; Greene AK; Landrigan-Ossar M; Paltiel HJ; Trenor CC; Kozakewich HP
J Pediatr Orthop; 2014 Jan; 34(1):109-17. PubMed ID: 24322574
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of Fibro-Adipose Vascular Anomaly with Sirolimus.
Wang Z; Yan H; Ding Y; Gong Y; Ma Y; Yao W; Li K
J Pediatr Surg; 2023 Jul; 58(7):1337-1341. PubMed ID: 36898877
[TBL] [Abstract][Full Text] [Related]
10. Analysis of mTOR pathway expression in lymphatic malformation and related diseases.
Hori Y; Ozeki M; Hirose K; Matsuoka K; Matsui T; Kohara M; Tahara S; Toyosawa S; Fukao T; Morii E
Pathol Int; 2020 Jun; 70(6):323-329. PubMed ID: 32067331
[TBL] [Abstract][Full Text] [Related]
11. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
13. Fibroadipose vascular anomaly: a clinicopathological study of 75 cases.
Xue S; Liu Q; Zhao Y; Kong L; Fu F; Gong Y; Guo X; Dong C; Wang M
Histopathology; 2023 Aug; 83(2):286-297. PubMed ID: 37099413
[TBL] [Abstract][Full Text] [Related]
14. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
15. Fibro-Adipose Vascular Anomaly (FAVA): Not Another Vascular Anagram.
Barwad A; Narwal A; Dutta R; Behera R; Kumar VS; Rastogi S; Mridha AR
Int J Surg Pathol; 2023 Jul; ():10668969231188419. PubMed ID: 37461272
[No Abstract] [Full Text] [Related]
16. Somatic activating mutations in
Rodriguez-Laguna L; Agra N; Ibañez K; Oliva-Molina G; Gordo G; Khurana N; Hominick D; Beato M; Colmenero I; Herranz G; Torres Canizalez JM; Rodríguez Pena R; Vallespín E; Martín-Arenas R; Del Pozo Á; Villaverde C; Bustamante A; Ayuso C; Lapunzina P; Lopez-Gutierrez JC; Dellinger MT; Martinez-Glez V
J Exp Med; 2019 Feb; 216(2):407-418. PubMed ID: 30591517
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
[TBL] [Abstract][Full Text] [Related]
19. Lower Extremity Fibro-Adipose Vascular Anomaly-Case Report.
Ferreira J; López Gutiérrez JC; Carneiro A; Sousa PP; Braga S; Simões JC; Carrilho C; Mesquita A
Ann Vasc Surg; 2020 Jul; 66():671.e15-671.e18. PubMed ID: 32018020
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.
Blesinger H; Kaulfuß S; Aung T; Schwoch S; Prantl L; Rößler J; Wilting J; Becker J
PLoS One; 2018; 13(7):e0200343. PubMed ID: 29985963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
